Fig. 4: High expression of AKR1C1 predicts poor efficacy of first-generation EGFR-TKIs in advanced LUAD patients harboring EGFR-mutation. | Cell Death Discovery

Fig. 4: High expression of AKR1C1 predicts poor efficacy of first-generation EGFR-TKIs in advanced LUAD patients harboring EGFR-mutation.

From: NEAT1_1 confers gefitinib resistance in lung adenocarcinoma through promoting AKR1C1-mediated ferroptosis defence

Fig. 4

A Representative IHC image of AKR1C1 (brown) in LUAD tissues. Scale bars, 50 μm. B Kaplan-Meier analysis curves showing the difference in PFS and OS between patients with high (n = 28) and low (n = 32) expression of AKR1C1 in the tumor tissues before initial treatment. C Multivariate Cox proportional hazards analysis of prognostic variables for DFS and OS in LUAD patients. D IHC staining scores of AKR1C1 in EGFR-TKI-resistant LUAD tissues and the tissues before initial treatment. E Kaplan-Meier analysis curves showing the difference in PFS between patients with high (n = 23) and low (n = 13) expression of AKR1C1 in the LUAD tissues without T790M when gefitinib resistance occurred. F Kaplan-Meier analysis curves showing the difference in OS between patients with high (n = 5) and low (n = 15) expression of AKR1C1 in the LUAD tissues with T790M when gefitinib resistance occurred. G Kaplan-Meier analysis curves showing the difference in OS between patients with high (n = 23) and low (n = 13) expression of AKR1C1 in the LUAD tissues without T790M when gefitinib resistance occurred. H Kaplan-Meier analysis curves showing the difference in OS between patients with high (n = 5) and low (n = 15) expression of AKR1C1 in the LUAD tissues with T790M when gefitinib resistance occurred. *P < 0.05.

Back to article page